Canterbury DHB

Context

August 2013

don't forget to update the issue and next review variables!!!

Changes in this release

Topic or section

Brief description

Reviewer

Pre-Treatment Investigations

Removed mention of ESR testing for AML/APL.

Ruth Spearing

Venous Thromboembolism - DVT and PE

Removed topics that are also in Blue Book and replaced them with link to Blue Book.

Emma Harding

Tumour Lysis Syndrome

Added link to a review of TLS.

Andrew Butler

PHARMAC Rules and Regulations

Cancer Exceptional Circumstances is now Named Patient Pharmaceutical Assessment (NPPA), and anagrelide doesn't require SA.

Bevan Harden

About this Canterbury DHB document (71348):

Document Owner:

Not assigned (see Who's Who)

Issue Date:

Next Review:

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 71348